Orifarm, officially known as Orifarm Group, is a prominent player in the pharmaceutical industry, headquartered in Denmark (DK). Founded in 1994, the company has established itself as a leader in the development, production, and distribution of generic medicines and parallel imports, primarily serving the European market. With a strong focus on quality and accessibility, Orifarm offers a diverse portfolio of products, including prescription medications and over-the-counter solutions. Their commitment to innovation and sustainability sets them apart in a competitive landscape. Over the years, Orifarm has achieved significant milestones, including expanding its operational reach across multiple European countries. The company is recognised for its dedication to improving patient access to essential medicines, solidifying its position as a trusted partner in the healthcare sector.
How does Orifarm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Orifarm's score of 43 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Orifarm reported total carbon emissions of approximately 11,949,000 kg CO2e. This figure includes 4,420,000 kg CO2e from Scope 1 emissions and 7,529,000 kg CO2e from Scope 2 emissions. The company has set ambitious targets to reduce its greenhouse gas emissions, committing to a 54.6% reduction in both Scope 1 and Scope 2 emissions by 2033, using 2023 as the baseline year. Additionally, Orifarm aims for a 32.5% reduction in Scope 3 emissions within the same timeframe. Over the past few years, Orifarm has demonstrated a commitment to sustainability, with total emissions decreasing from approximately 12,579,000 kg CO2e in 2022 to the current figure. The company is also a member of the Science Based Targets initiative (SBTi), aligning its goals with the global aim to limit warming to 1.5°C. Furthermore, Orifarm has made a long-term commitment to achieve net-zero emissions across all scopes by 2050. These initiatives reflect Orifarm's dedication to reducing its carbon footprint and contributing to global climate action, positioning itself as a responsible player in the pharmaceuticals, biotechnology, and life sciences sector.
Access structured emissions data, company-specific emission factors, and source documents
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|
Scope 1 | 732,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 575,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orifarm is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.